Skip to main content
TipRanks
Go Ultimate75% OFF

Pacific Hospital Supply Co., Ltd. (4126) AI Stock Analysis

TW:4126

Pacific Hospital Supply Co., Ltd.

(TPEx:4126)

Select Model
Rating:68Neutral
Price Target:TWD 80.00â–²(6.67% Upside)
Action:initiatedcoverage
Date:11/09/26

Pacific Hospital Supply scores above average, anchored by a fortress balance sheet, dependable free cash flow and high-quality earnings. Valuation support is strong, with a modest 12.4x P/E and a 6.1% dividend yield backed by ample cash generation. Offsetting this are two concerns: margins compressed across the board last year and net income fell ~14% on low single-digit revenue growth, and the share price is in a downtrend below all key moving averages with negative MACD. The result is a stable, income-oriented holding whose re-rating likely depends on evidence of margin and earnings recovery.

Positive Factors
Consistent ProfitabilityConsistently healthy gross, operating, and net margins indicate an established business model with meaningful earnings power. This profitability provides resources for reinvestment, shareholder returns, and resilience over the next several quarters even when revenue growth is uneven.
Negative Factors
Recent Revenue ContractionThe 2025 revenue decline interrupts the prior growth trend and signals weaker recent demand or business momentum. If this contraction persists, it could limit operating leverage, reduce reinvestment capacity, and make it harder for earnings to return to their earlier growth path.

Pacific Hospital Supply Co., Ltd. (4126) vs. SPDR S&P 500 ETF (SPY)

-15%-10%-5%0%5%10%15%20%TW:4126-10.19%SPY+14.28%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 5.40B
Dividend Yield
6.00%
Average Volume (3M)
33.73K
Price to Earnings (P/E)
12.5
Beta (1Y)
0.11
Revenue Growth
1.32%
EPS Growth
7.25%
Country
TW
Employees
812
Sector
General
Sector Strength
55
Industry
Medical - Specialties

Pacific Hospital Supply Co., Ltd. Business Overview & Revenue Model

Company Description

Pacific Hospital Supply Co., Ltd., together with its subsidiaries, manufactures, processes, and sells medical disposable products and equipment in Taiwan. The company’s disposable medical devices include tubings, bags, bottles, closed wound drainage...

Pacific Hospital Supply Co., Ltd. Financial Statement Overview

Summary

A financially conservative, cash-generative medical products maker. The balance sheet (85) is the standout: debt-to-equity of just 0.15, equity funding ~76% of assets and ROE of 12.9%. Cash flow (78) is healthy, with operating cash flow of ~NT$542m exceeding net income (1.04x) and free cash flow of ~NT$468m on light capex, though year-to-year conversion has been uneven. The income statement (68) is the weak link: revenue grew only modestly to ~NT$2.41bn while gross, operating and net margins all compressed, driving net income down ~14% to NT$382.9m. Overall: low financial risk and reliable cash, but a softening earnings trajectory.

Income Statement

68Positive

Balance Sheet

85Very Positive

Cash Flow

78Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue2.42B2.41B2.35B2.32B2.18B2.02B
Gross Profit722.62M724.71M746.84M739.75M587.97M523.42M
EBITDA663.67M612.06M699.23M673.80M568.57M602.81M
Net Income434.16M382.87M447.85M420.79M331.40M386.42M
Balance Sheet
Total Assets4.19B3.92B3.88B3.77B3.65B3.80B
Cash, Cash Equivalents and Short-Term Investments1.39B1.16B1.10B990.62M688.29M815.27M
Total Debt430.79M432.89M432.30M437.43M439.53M675.73M
Total Liabilities1.33B951.83M939.57M934.34M929.03M1.09B
Stockholders Equity2.86B2.97B2.94B2.83B2.72B2.71B
Cash Flow
Free Cash Flow480.04M467.89M456.57M620.72M394.15M285.14M
Operating Cash Flow568.21M542.15M505.24M653.63M431.66M319.11M
Investing Cash Flow-221.18M-75.22M-150.78M-273.74M-26.31M382.65M
Financing Cash Flow-375.18M-374.87M-358.76M-312.72M-564.34M-482.49M

Pacific Hospital Supply Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TW:4126 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TW:4166TW:416670OutperformTWD 5.47B22.78――――
TW:4126TW:412668NeutralTWD 5.39B12.54―6.00%1.32%7.25%
TW:4746TW:474664NeutralTWD 5.43B11.42―6.61%-2.71%―
TW:1788TW:178863NeutralTWD 5.57B14.19―5.56%7.58%13.04%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TW:4164TW:416455NeutralTWD 4.79B21.84―4.45%11.83%27.86%
TW:4119TW:411948NeutralTWD 5.85B95.69―1.55%-18.83%-87.54%

* General Sector Average

Performance Comparison

-40%-20%0%20%TW:4126TW:1788TW:4119TW:4164TW:4166TW:4746Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:4126 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:4126Pacific Hospital Supply Co., Ltd.75.00-8.60-10.29%
TW:1788Hi-Clearance Inc.126.00-4.42-3.39%
TW:4119SCI Pharmtech Corp.48.50-0.61-1.25%
TW:4164CHC Healthcare Group24.90-15.67-38.63%
TW:4166Orient Pharma Co., Ltd.22.55-2.05-8.33%
TW:4746Formosa Laboratories, Inc.45.40-15.89-25.92%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026